- LOTTE Biologics has signed a contract development and manufacturing agreement with a Japan-based global pharmaceutical company.
- The partnership aims to support biologics development and manufacturing while strengthening collaboration in the Japanese market.
LOTTE Biologics has signed a contract development and manufacturing (CDMO) agreement with a Japan-based global pharmaceutical company. The announcement marks a step in the company’s efforts to expand its presence in biologics development and contract manufacturing.
The agreement focuses on establishing a collaboration framework for biologics development and manufacturing. While specific project details were not disclosed, the partnership is intended to support joint activities in these areas.
The collaboration is also expected to contribute to LOTTE Biologics’ positioning in the global market, including Japan. The company indicated that the agreement could serve as a starting point for further cooperation with the partner.
LOTTE Biologics stated that the partnership aligns with its broader strategy to strengthen its CDMO capabilities and expand its international footprint in biologics manufacturing.
No financial terms or timelines related to the agreement were disclosed.
